Thursday, 11 June 2020 14:01

Victoria Fernández, Janssen Iberia legal director

Janssen, the pharmaceutical division of Johnson & Johnson present in over 150 countries, is one of the major "Pharmas" that, since the beginning of the pandemic, launched a search for a vaccine against COVID-19

The company plans to begin Phase   1   clinical trials in humans with its vaccine in September 2020 and expects the first batches of the vaccine to prevent COVID-19   to be available for use in emergency situations in early 2021, a   significantly faster than usual process for vaccine development.    Iberian       Lawyer interviewed       Victoria   Fernandez, head of   Janssen’s legal department in   Iberia, to learn more about the work of a    pharmaceutical company like Janssen at this critical time.

Victoria Fernández (pictured) is the legal director of Janssen Iberia. Her main responsibility is, as she tells us, is giving legal support to the pharmaceutical companies of the international group Johnson & Johnson in Spain and Portugal. Her team consists of a direct group of six people, to which we can add the structure exclusively dedicated to clinical research contracts.

What led you to work as an in-house lawyer in the pharmaceutical industry? What would you highlight about Janssen as a professional environment and what kind of values does the firm stand for?

It was a decision based on professional development, after a long and fruitful period as a lawyer in a prestigious firm, during which I learned a lot and, even more importantly, from which I have made friends for life. As we say among ourselves “I came to a client.” Janssen’s appeal was a “blend” of ingredients: the novelty of working within a growing company, a strong, competitive business sector dedicated to improving patient health as the innovative pharmaceutical industry is. I discovered the values that Janssen stands for from the inside. They are best described in our code of ethics, which we call “Our Credo” and which has been in force at Johnson & Johnson since 1943. It includes our company’s priorities for our patients and users, customers, employees, shareholders and the communities in which we live.

In your current role, what is the most challenging situation you have faced as an in-house lawyer, and would you say that the most important challenges pharmaceutical company lawyers will have to face in the coming years are those concerning the Compliance area?

I believe the biggest challenge has been helping to shape solutions to the limitations and/or delay with which patients access a new medicine or a new indication in Spain or Portugal.

In the area of Compliance, I would say that the lawyers of innovative pharmaceutical companies have already come a long way, driven by the application of the FCPA and other anti-corruption rules and the soft-law or self-regulation embodied in the EFPIA, Pharma industry, Apipharma and internal Codes. In Pharma, we dedicate and will continue to dedicate many resources to Compliance. In my opinion, the real challenge of the next few years for the lawyers of innovative pharmaceutical companies like Janssen is going to be how to integrate digitalization, Big Data and artificial intelligence into health research. The use, nationally or internationally, of existing and future databases must not be hampered in the European Union by unsuitable regulation of clinical trials, or by an inadequate understanding of personal data protection (Privacy), fundamentally.

In the context of the pandemic we are experiencing, many pharmaceutical companies have launched a search for a vaccine. We understand that, in turn, the monitoring mechanisms for these vaccines to meet the safety/efficacy requirements have been strengthened through the international bodies created for this purpose. How is the development of a vaccine experienced from a legal point of view?

The real protagonists in the search for a vaccine, as in all pharmaceutical innovation, are the researchers, both inside and outside. We help pharmaceutical innovation by closing agreements that allow for the articulation of research alliances and collaboration with governments or public and private institutions, universities, hospitals and health professionals. Health research is not easy. The authorities have regulations that ensure compliance with the guarantees of safety and efficacy of the vaccines under investigation, which already provide for emergency mechanisms that reduce deadlines without detracting from these requirements. We collaborate in the compliance of the regulation that integrates the so-called “Pharmaceutical Law”, a “great unknown” in the legal world if compared to other legal branches.

The COVID-19 requires absolute attention and other projects have been momentarily halted. Has this caused special demands on your department?

Yes, the Covid-19 has provoked in many of us the need to help, in the midst of uncertainty about everything around us. My department, like the rest in our company, has turned to telework from home, giving continuity to the work, while taking care of their families. Many emergencies have arisen and we have helped to attend to them: emergency donations, ensuring the continuity of the supply of medicines to all patients, now at home, continuing, where possible, the research contracts. As a lawyer, it is difficult to follow a BOE “that sparks”, with an unprecedented profusion of legislation that requires the study of new, rapidly modified regulations, because they affect many and varied aspects of our activity.

By Desiré Vidal

To read the interview in full please download issue N.95 here

More in this category: « At high speed Respecting the brand »

Iberian Lawyer
N.96 • July-August 2020

IL94 cover SP IL94 cover EN

The Latin American Lawyer
N.14 • July - August 2020

LAL12 cover EN

legalinnovation webbanner 300x100px v2

Lexpo20 webbanner 300x100px v2

FortuUnder40awards Banner 300x250 CallForSub 2

IL LabourAwardsPT 300x100 Finalists3

IL Lawit 300X100 October

IL LabourAwardsSP 300x100 Finalists3

IL LatamAwards STD 300x100 1

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the IberianLawyer website. However, you can change your cookie settings at any time. Learn more

I agree

What do I need to know about cookies?

A cookie is a small text file that’s stored on your computer or mobile device when you visit a website. We use them to:

  • Remember your preferences
  • Tailor our sites to your interests.

There are different types of cookies

First party cookies

These are set by the website you’re visiting. And only that website can read them.  In addition, a website might use a separate company to analyse how people are using their site. And this separate company will set their own cookie to do this.

Third party cookies

These are set by someone other than the owner of the website you’re visiting. 

Some IberianLawyer web pages may also contain content from other sites like Vimeo or Flickr, which may set their own cookies. Also, if you Share a link to a IberianLawyer page, the service you share it on (e.g. Facebook) may set a cookie on your browser.

The IberianLawyer has no control over third party cookies.

Advertising cookies

Some websites use advertising networks to show you specially targeted adverts when you visit. These networks may also be able to track your browsing across different sites.

IberianLawyer site do use advertising cookies but they won’t track your browsing outside the IberianLawyer.

Session cookies

These are stored while you’re browsing. They get deleted from your device when you close your browser e.g. Internet Explorer or Safari.

Persistent cookies

These are saved on your computer. So they don’t get deleted when you close your browser.

We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.

Other tracking technologies

Some sites use things like web beacons, clear GIFs, page tags and web bugs to understand how people are using them and target advertising at people.

They usually take the form of a small, transparent image, which is embedded in a web page or email. They work with cookies and capture data like your IP address, when you viewed the page or email, what device you were using and where you were.

How does the Iberian Lawyer use cookies?

We use different types of cookies for different things, such as:

  • Analysing how you use the IberianLawyer
  • Giving you a better, more personalised experience
  • Recognising when you’ve signed in

Strictly Necessary cookies

These cookies let you use all the different parts of Iberian Lawyer. Without them services that you have asked for cannot be provided.

Some examples of how we use these cookies are:

  • Signing into the IberianLawyer
  • Remembering previous actions such as text entered into a registration form when navigating back to a page in the same session
  • Remembering security settings which restrict access to certain content.

Performance cookies

These help us understand how people are using the IberianLawyer online, so we can make it better. And they let us try out different ideas.
We sometimes get other companies to analyse how people are using the IberianLawyer online. These companies may set their own performance cookies You can opt out of these cookies here.Some examples of how we use these cookies are:

  • To collect information about which web pages visitors go to most often so we can improve the online experience
  • Error management to make sure that the website is working properly
  • Testing designs to help improve the look and feel of the website.
Cookie nameWhat it's for
Google DoubleClick The IberianLawyer uses Google DoubleClick to measure the effectiveness of its online marketing campaigns.Opt-out of DoubleClick cookies
Google Analytics From time to time some IberianLawyer online services, including mobile apps, use Google Analytics. This is a web analytics service provided by Google, Inc. Google Analytics sets a cookie in order to evaluate use of those services and compile a report for us.Opt-out of Google Analytics cookies